New emerging biological markers of neonatal sepsis

| 2017 | 1 cell‐surface antigens are nonspecific biomarkers that have been extensively studied for the diagnosis and management of LONS. Serum amyloid A increases up to 1000‐fold in response to inflammation‐associated reactive amyloidosis. The utility of hepcidin as a regulator of inflammation for the diagnosis of late‐onset sepsis in very low birth weight infants was recently evaluated.[4] Ischemia‐modified albumin (IMA) has been advocated as a biomarker of oxidative stress in different pathologies, and the levels of IMA were positively correlated with white blood cell count, CRP, and PCT in the sepsis group before treatment. Therefore, the serum IMA levels may be useful in LONS at the time of diagnosis and after therapy.[5]